tirzepatide approved for obesity (ZEPBOUND) Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Tirzepatide for Medical Weight Loss

Retatrutides glucagon receptor activation shifts this effect toward increased energy expenditure rather than elevated blood sugar

The Humira LOE demonstrated that rebate architecture, not patent barriers, can be the most effective short-term defense against biosimilar erosion

Patients should report persistent or severe gastrointestinal symptoms to their GP or diabetes specialist, as dose adjustment may be necessary

Follow the manufacturers guidance, but most remain sterile for years if packaging is intact

92 Luseogliflozin is a selective SGLT-2 inhibitor that received marketing approval on March 24, 2014, for the treatment of T2DM

Risk factors stack, and understanding your personal risk profile allows for better prevention strategies